Ribometrix is a biotechnology company pioneering a new class of small-molecule therapeutics that directly target the three-dimensional structures of RNA to modulate disease biology. By leveraging a proprietary RNA structural discovery platform, the company is discovering novel small molecules that bind to RNA and influence the production of disease-causing proteins, unlocking therapeutic opportunities that traditional approaches can’t access.